Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 4:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 3,908 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hypertension Clear all
Terminated Phase 4 Interventional Results available

Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan

NCT00840463
View directory record Official record
Conditions
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Interventions
Ambrisentan, Placebo
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2020 · Synced Oct 27, 2026, 4:34 AM EDT
Completed Not applicable Interventional

Health Literacy-Focused Program to Improve Blood Pressure Control in Korean Americans

NCT00406614
View directory record Official record
Conditions
Hypertension
Interventions
Health Literacy-Focused High Blood Pressure Intervention
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
60 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Ellicott City, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 27, 2026, 4:34 AM EDT
Completed Not applicable Interventional Results available

Intensive Versus Standard Blood Pressure Lowering to Prevent Functional Decline in Older People

NCT01650402
View directory record Official record
Conditions
Hypertension, Systolic, Cerebrovascular Disease
Interventions
Anti-hypertensive therapy to SBP 130 mm Hg, Anti-hypertensive therapy to SBP 145 mm Hg
Other
Lead sponsor
UConn Health
Other
Eligibility
75 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 27, 2026, 4:34 AM EDT
Completed No phase listed Observational

Survey of Patients Taking IOP-Lowering Eye Drops

NCT02384772
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Survey
Other
Lead sponsor
ForSight Vision5, Inc.
Industry
Eligibility
Not listed
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Oct 27, 2026, 4:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cuff(SZ): The Cuff Size Blood Pressure Measurement Trial

NCT04610775
View directory record Official record
Conditions
Hypertension, Blood Pressure, Cardiovascular Diseases, Cardiovascular Risk Factor
Interventions
Order of cuff sizes during blood pressure measurements
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Oct 27, 2026, 4:34 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

NCT05161481
View directory record Official record
Conditions
Hypertension, Portal
Interventions
Avenciguat (BI 685509), Placebo matching Avenciguat (BI 685509)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Pasadena, California • Rialto, California • Miami Lakes, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 27, 2026, 4:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Metabolic Effects of Different Weight Loss Diets

NCT00422630
View directory record Official record
Conditions
Metabolic Syndrome X, Obesity, Insulin Resistance, Hypertension, Diabetes
Interventions
The DASH diet, The low glycemic Index Diet, Reduced calorie American Diet
Behavioral
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2011 · Synced Oct 27, 2026, 4:34 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 27, 2026, 4:34 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

EVALUATION of CATS TONOMETER PRISM in LASIK SUBJECTS

NCT06266351
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension, Normal Tension Glaucoma
Interventions
This is observational IOP measurement
Device
Lead sponsor
Intuor Technologies, Inc.
Industry
Eligibility
22 Years and older
Enrollment
198 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Tucson, Arizona • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 27, 2026, 4:34 AM EDT
Recruiting Not applicable Interventional

CardioCare Quest: A Co-created Game for Improving Hypertension Treatment Compliance in Arizona

NCT06487637
View directory record Official record
Conditions
High Blood Pressure
Interventions
CardioCare Quest
Behavioral
Lead sponsor
Northern Arizona University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Flagstaff, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 27, 2026, 4:34 AM EDT
Completed Not applicable Interventional

Using an Electronic Personal Health Record to Empower Patients With Hypertension

NCT01317537
View directory record Official record
Conditions
Hypertension
Interventions
Electronic personal health record
Other
Lead sponsor
Augusta University
Other
Eligibility
21 Years to 80 Years
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 17, 2011 · Synced Oct 27, 2026, 4:34 AM EDT
Recruiting Phase 1 Interventional

Metabolic Effects of Angiotensin-(1-7)

NCT02646475
View directory record Official record
Conditions
Obesity, Insulin Resistance, Hypertension, Metabolic Cardiovascular Syndrome
Interventions
Angiotensin-(1-7), Saline
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 27, 2026, 4:34 AM EDT
Completed Phase 3 Interventional Results available

Ranolazine and Pulmonary Hypertension

NCT01174173
View directory record Official record
Conditions
Angina, Pulmonary Arterial Hypertension
Interventions
Ranolazine
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Oct 27, 2026, 4:34 AM EDT
Terminated Phase 2 Interventional Results available

Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism

NCT02001051
View directory record Official record
Conditions
Subclinical Hypercortisolism, Cushing Syndrome, Adrenal Neoplasm
Interventions
Adrenalectomy, Observation
Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 27, 2026, 4:34 AM EDT
Completed Phase 2 Interventional

Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH)

NCT01966302
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
BPS-314d-MR
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 27, 2026, 4:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Watermelon Dose Response Blood Pressure Study

NCT05892328
View directory record Official record
Conditions
Pre-hypertension, Cardiovascular Diseases
Interventions
Watermelon Flesh Dose 1, Watermelon Flesh Dose 2, Control
Other
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Industry
Eligibility
25 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 27, 2026, 4:34 AM EDT
Completed Not applicable Interventional

Renin Profiling in Selection of Initial Antihypertensive Drug

NCT00834600
View directory record Official record
Conditions
Hypertension
Interventions
olmesartan, hydrochlorothiazide, amlodipine, hydrochlorothiazide (HCTZ) or olmesartan
Drug
Lead sponsor
The Louis & Rachel Rudin Foundation
Other
Eligibility
40 Years to 85 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
5
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Oct 27, 2026, 4:34 AM EDT
Completed Phase 2 Interventional Results available

Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypertension

NCT04910100
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Nebivolol Ophthalmic Suspension 1 Percent, Nebivolol Ophthalmic Suspension 0.5 Percent, Timolol Ophthalmic Suspension 0.5 Percent, Timolol Ophthalmic Solution 0.5 Percent
Drug
Lead sponsor
Betaliq, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 27, 2026, 4:34 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension

NCT05564637
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Interstitial Lung Disease, Healthy Adults
Interventions
Treprostinil, Right Heart Catheterization (RHC) while exercising, Optional Muscle Biopsy
Drug · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 27, 2026, 4:34 AM EDT
Completed Not applicable Interventional

Healthy Oils for Women (HOW Study)

NCT02063165
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
High Linoleic Safflower Oil
Dietary Supplement
Lead sponsor
Ohio State University
Other
Eligibility
50 Years to 69 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 27, 2026, 4:34 AM EDT
Completed Phase 3 Interventional

Efficacy, Safety, & Pharmacokinetics of Candesartan Cilexetil in Hypertensive Paediatric Subjects 6 to < 17 Years of Age

NCT00244595
View directory record Official record
Conditions
Hypertension
Interventions
candsartan cilexetil
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 17 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
37
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2009 · Synced Oct 27, 2026, 4:34 AM EDT
Completed No phase listed Observational

Prediction of 30-Day Readmission Using Machine Learning

NCT04849312
View directory record Official record
Conditions
Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 27, 2026, 4:34 AM EDT
Completed Phase 3 Interventional Results available

A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension

NCT00667719
View directory record Official record
Conditions
Essential Hypertension
Interventions
Aliskiren, Amlodipine, Hydrochlorothiazide
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Oct 27, 2026, 4:34 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Role of ASpirin in Placental and Maternal Endothelial Cell Regulation IN Pre-eclampsia

NCT03893630
View directory record Official record
Conditions
Pre-Eclampsia
Interventions
Acetylsalicylic Acid 81 mg, Acetylsalicylic Acid 162 mg, Control
Drug · Other
Lead sponsor
John O'Brien, MD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 27, 2026, 4:34 AM EDT